HIV/AIDS Drug Development
HIV fusion inhibitor enfuvirtide has a favorable safety and tolerability profile
Published in Blood Weekly, June 30th, 2005
"Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity.
"Treatment-experienced patients, who have failed therapy owing to the emergence of drug-resistant virus, have a significant unmet medical need," wrote scientists in the journal Expert Opinion on Pharmacotherapy.
"Enfuvirtide...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-06-30)
More Articles from Blood Weekly
- Angiology
Transillumination tomography used for imaging of tissue-engineered blood vessels - Bioartificial Liver
Directed differentiation of bone marrow cells yields hepatocyte-like cells - Blood Group Typing
Microarray assay used to type DNA and detect new alleles in donor cohorts - Red Blood Cell Substitute
Red blood cell substitute has no significant side effects - Transfusion Medicine
Pooling of whole blood platelets does not lower efficacy - Adenovirus Outbreak
Neonatal ICU adenovirus type 30 outbreak spread via ophthalmologic procedures - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
